bluebird bio, Inc. (BLUE)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 4.3200 |
| Open | 3.6800 |
| Bid | 3.2200 x 3100 |
| Ask | 3.2800 x 2200 |
| Day's range | 2.9501 - 3.7400 |
| 52-week range | 2.8700 - 8.5800 |
| Volume | |
| Avg. volume | 4,177,123 |
| Market cap | 335.529M |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Bluebird Bio (BLUE) Reports Q4 Loss, Misses Revenue Estimates
Bluebird (BLUE) delivered earnings and revenue surprises of -26.67% and 99.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
1 Beaten-Down Stock That Has a Lot to Prove in 2023
The past several years have been brutal for biotech company Bluebird bio (NASDAQ: BLUE). Shares of the gene-editing specialist are down by 85% since early 2020 as it has had to deal with clinical and regulatory setbacks, not to mention the marketwide headwinds that have impacted all equities.
© 2023 Yahoo. All rights reserved.
